Disclosed are compounds of formulae:

##STR00001##

and salts, hydrates, or solvates thereof, where R.sub.1, R.sub.2, R.sub.3, R.sub.5, and R.sub.6 are defined herein, compositions containing these compounds, methods of preparing these compounds, and methods of using these compounds in a variety of applications, such as a surfactant or additive in personal care products.

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. ##STR00001##

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. ##STR00001##

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

Process for preparing primary amines which have at least one functional group of the formula (CH.sub.2NH.sub.2) and at least one further primary amino group by alcohol amination of starting materials having at least one functional group of the formula (CH.sub.2OH) and at least one further functional group (X), where (X) is selected from among hydroxyl groups and primary amino groups, by means of ammonia with elimination of water, wherein the reaction is carried out homogeneously catalyzed in the presence of at least one complex catalyst comprising at least one element selected from groups 8, 9 and 10 of the Periodic Table and also at least one donor ligand.

Process for preparing primary amines which have at least one functional group of the formula (CH.sub.2NH.sub.2) and at least one further primary amino group by alcohol amination of starting materials having at least one functional group of the formula (CH.sub.2OH) and at least one further functional group (X), where (X) is selected from among hydroxyl groups and primary amino groups, by means of ammonia with elimination of water, wherein the reaction is carried out homogeneously catalyzed in the presence of at least one complex catalyst comprising at least one element selected from groups 8, 9 and 10 of the Periodic Table and also at least one donor ligand.

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.7, R.sup.8, R.sup.9, L.sup.1, L.sup.2, G.sup.1, G.sup.2, G.sup.3, b, and c are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.7, R.sup.8, R.sup.9, L.sup.1, L.sup.2, G.sup.1, G.sup.2, G.sup.3, b, and c are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

##STR00001##